Review Article

Efficacy and Safety of Sinomenine Preparation for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Randomized Controlled Trials

Table 2

Characteristics of the studies included.

Study IDSample size (E/C)Sex (M/F)Age (mean ± SD or range)Duration of disease (Mean ± SD or range)InterventionFollow-up timeOutcomes
ECECECEC

Liu [39]36/3229/724/824.0 ± 4.822.0 ± 5.4(4.8 ± 3.6) y(4.5 ± 3.2) ySP (ZFCT[po, 40 mg, tid]) + CPTCPT (SSZ)18 m①②③④⑤⑥⑦⑧
Liu [40]30/2026/418/215∼3917∼58(0.5∼5) y(0.5∼6) ySP (ZFCT[po, 80 mg, tid]) + CPTCPT (SSZ)3 m④⑦⑧⑨
Dong [41]45/3442/332/224∼7226∼72NANASP (ZFCT[po, 40 mg, tid]) + CPTCPT (SSZ + Meloxicam)24 w (6 m)①②④⑤⑥⑧⑨
Yang [42]38/3831/733/530.26 ± 13.428.67 ± 12.8(5.31 ± 2.8) y(6.04 ± 3.1) ySP (ZFSRT[po, 60 mg, bid]) + CPTCPT (SSZ)12 w (3 m)①②③④⑤⑥⑦⑧⑨⑩
Huang [43]13/12NANANANANANASP (ZFSRT[po, 60 mg, bid]) + CPTCPT (SSZ)6 m①②⑤⑦⑧⑨
Yin [44]31/3028/625/926.4 ± 3.529.8 ± 2.2(5.9 ± 1.8) y(6.1 ± 4.2) ySP (ZFSRT[po, 60 mg, bid]) + CPTCPT (SSZ)12 m①⑥⑧⑪⑫
Lin [45]57/58NANA23.5 ± 13.424.7 ± 11.33 m∼11 y5 m∼12 ySP (ZFSRT[po, 120 mg, bid]) + CPTCPT (SSZ + NSAIDs + methotrexate)12 m①②③④⑤⑥⑦⑧⑨⑩
Yu [46]40/4032/830/1027.2 ± 3.026.7 ± 3.3(6.1 ± 1.2) y(5.7 ± 1.5) ySP (ZFSRT[po, 120 mg, bid]) +CPTCPT (SSZ + Thalidomide + Meloxicam)3 m①③④⑤⑥⑦⑨⑪
Jie [47]32/30NRNRNR.NRNRNRSP (ZFI[intra-articular injection, 35 ml, once a week]) + CPTCPT (SSZ/Meloxicam)1 m②③⑤⑥⑦⑧⑪⑫
An [48]25/2419/620/430.2 ± 8.031.3 ± 7.0(6.3 ± 1) y(6.9 ± 0.8) ySP (ZFI[intra-articular injection, 2 ml, qod]) + CPTCPT (IPT + vitamins + Ranitidine)1 m
Liu [49]60/60NANA26.5 ± 4.826 ± 4.56 m∼14 y6 m∼13 ySP (ZFSRT[po, 60 mg, bid])CPT (SSZ)3 m①②③④⑤⑥⑦⑧⑨
Chai [50]28/2222/629/728.63 ± 5.2327.98 ± 3.85(4.87 ± 1.09) y(4.91 ± 1.27) ySP (ZFSRT[po, 120 mg, bid])CPT (SSZ)2 m①②③④⑤⑥⑦⑧

Note. E: experimental group; C: control group; M: male; F: female; ZFCT: Zhengqing Fengtongning Conventional Tablet; ZFSRT: Zhengqing Fengtongning Sustained Release Tablet; ZFI: Zhengqing Fengtongning Injection; SSZ: sulfasalazine; NSAIDs: nonsteroidal anti-inflammatory drugs; IPT: inflammatory pain tablet; po: oral preparation; tid: three times a day; bid: twice a day; qod: every other day; y: year; m: month; w: week; NA: not available; ① morning stiffness time; ② Schober test; ③ chest expansion; ④ occipital wall test; ⑤ erythrocyte sedimentation rate (ESR); ⑥ C-reactive protein (CRP); ⑦ total effective rate; ⑧ adverse reactions; ⑨ finger-to-ground distance; ⑩ 15 m walking time; ⑪ Bath ankylosing spondylitis disease activity index (BASDAI); ⑫ Bath ankylosing spondylitis functional index (BASFI).